In Brief: IsoStent
This article was originally published in The Gray Sheet
IsoStent: Receives investigational device exemption from FDA Aug. 2 to begin Phase I clinicals of radioisotope-implanted versions of Johnson & Johnson's Palmaz-Schatz coronary stent for the treatment of restenosis. The 30-patient trial will be conducted at three clinical sites in the U.S., with patient follow up at one, six and 12 months, the San Carlos, California firm says. In addition, J&J purchases "an additional equity stake" in IsoStent "but remains a minority owner of the company." In April, the two firms announced an agreement under which J&J will provide R&D support to IsoStent as well as an initial minority investment ("The Gray Sheet" April 22, I&W-1). With the additional investment, J&J's Cordis subsidiary receives an option to exclusively market IsoStent products worldwide...
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.